Why the study?
Although anti-inflammatory drugs have shown potential efficacy in preventing post-MI LV remodeling, systemic administration causes off-target side effects.
Does targeted myocardial delivery of anti-inflammatory drugs via nanoparticle-based drug delivery models prevent post-MI remodeling in patients with ischemia-induced heart failure?
Does targeted myocardial delivery of anti-inflammatory drugs via nanoparticle-based drug delivery models prevent post-MI remodeling in patients with ischemia-induced heart failure?
Nanoparticle-based targeted delivery of anti-inflammatory drugs offers a promising strategy to mitigate post-MI left ventricular remodeling and heart failure while minimizing systemic side effects.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for targeted anti-inflammatory delivery in ischemic HF; leaves open efficacy and feasibility for randomized trials.
Ongoing advancements in the treatment of acute myocardial infarction (MI) have significantly decreased MI related mortality. Consequently, the number of patients experiencing post-MI heart failure (HF) has continued to rise. Infarction size and the extent of left ventricular (LV) remodeling are largely determined by the extent of ischemia at the time of myocardial injury. In the setting of MI or acute phase of post-MI LV remodeling, anti-inflammatory drugs including intravenous immunoglobulin (IVIG) and Pentoxifylline have shown potential efficacy in preventing post-MI remodeling in-vitro and in some clinical trials. However, systemic administration of anti-inflammatory drugs are not without their off-target side effects. Herein, we explore the clinical feasibility of targeted myocardial delivery of anti-inflammatory drugs via biodegradable polymers, liposomes, hydrogels, and nano-particle based drug delivery models (NDDM) based on existing pre-clinical and clinical models. We summarize the barriers to clinical application of targeted anti-inflammatory delivery post-MI, including challenges in achieving sufficient retention and distribution, as well as the potential need for multiple dosing. Collectively, we suggest that localized delivery of anti-inflammatory agents to the myocardium using NDDM is a promising approach for successful treatment of ischemic HF. Future studies will be instrumental in determining the most effective target and delivery modalities for orchestrating NDDM-mediated treatment of HF.
No takes yet. Share an insight, caveat, or question.
Haley et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: